Luciano Costa, MD, PhD; ASH 2025: CAR T Cell Brings Profound Benefit with Long-Term Progression-Free Survival in Patients with Standard...
Matteo Lambertini MD PhD; San Antonio Breast Cancer Symposium: ALTTO Trial Shows Adjuvant Aromatase Inhibitors Outperform Tamoxifen in...
Audio Journal of Oncology Podcast Jesse Tettero MD PhD; ASH 2025: Measurable Residual Disease Can Predict Overall Survival in Patients with...
Next Generation Sequencing-Assessed Minimum Residual Disease Identifies Young Patients with High-risk/Relapsed B-cell Acute Lymphoblastic...
2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with...
ASH 2025 Orlando: Childhood Leukemia Cured But Families Broke. “Financial Toxicity” is Often More Worrying than you...
Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies A...
An interview with Jeanne Tie MD, Medical Oncologist, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza...
Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast...
An interview with Li Zhang MD, Medical Oncologist and Full Professor, Sun Yat-sen University Cancer Center, Guangzhou, China BERLIN...
An interview with: , Director of Health Science Center, President, Sun Yat-sen Memorial Hospital, Guangzhou (SYSU), Guangzhou, China...
Audio Journal of Oncology Podcast Andrew Clamp MD, PhD, ESMO Berlin: Weekly Dose-Dose Chemotherapy Brings Big Survival Benefit for Patients...